Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in transplantation patients
The described invention comprises a method for detecting the onset or monitoring the recurrence of chronic graft versus host disease (cGVHD) in a transplantation patient. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from the transplantation patient and analyzing the isolated PBMCs to detect a biomarker specific for a donor cell. The detection of the biomarker is indicative of the onset or recurrence of cGVHD in the transplantation patient.
1. A method for treating chronic graft versus host disease (cGvHD) prior to appearance of symptoms of cGvHD in a patient following a hematopoietic cell transplantation therapy with a hematopoietic cell allograft comprising hematopoietic cells from a genetically distinct donor, comprising:
(a) isolating peripheral blood mononuclear cells (PBMCs) comprising the genetically distinct donor cells from the patient at a time after the therapy;
(b) detecting an alloreactive donor B cell population in the isolated PBMCs by detecting reactivity in vitro of a first biomarker presented on the alloreactive donor B cells with a second biomarker expressed by genetically distinct cells of the patient, the second biomarker having a differential label;
(c) initiating immune therapy to mitigate appearance of symptoms of cGvHD resulting from the hematopoietic cell transplant if alloreactive donor B cells are detected by step (b).
2. The method according to claim 1 , wherein the first biomarker is an antibody, the hematopoietic cell allograft contains cells that express the antibody, and the antibody reacts with the second biomarker expressed by the patient's cells.
3. The method according to claim 2 , wherein the second biomarker is a Y-chromosome encoded H-Y antigen.
4. The method according to claim 3 , wherein the H-Y antigen is the peptide sequence according to SEQ ID NO: 1.
5. The method according to claim 3 , wherein the recipient patient is male, the recipient's cells express the second biomarker, and the second biomarker is the Y-chromosome encoded H-Y antigen, the donor is female, the donor's cells express the first biomarker, and the first biomarker is an antibody, which binds to the second biomarker, which is the H-Y antigen expressed by the patient's cells, wherein the recipient patient and donor are genetically distinct.
6. The method according to claim 5 , wherein phenotype of the B lymphocytes is CD19 + .
7. The method according to claim 1 , wherein the time after therapy for detecting the first biomarker presented on circulating cells of the patient is within 1 year after transplantation.
8. The method according to claim 1 , wherein the time after therapy for detecting the first biomarker presented on circulating cells of the patient is within 180 days after transplantation.
9. The method according to claim 1 , wherein the time after therapy for detecting the first biomarker presented on circulating cells of the patient is within 155 days after transplantation.
10. The method according to claim 1 , wherein time after therapy for detecting of the first biomarker presented on circulating cells of the patient is within 90 days after transplantation.
11. The method according to claim 1 , wherein detecting of the first biomarker presented on circulating cells of the patient precedes development of circulating antibodies to a donor cell antigen in the patient.
12. The method according to claim 1 , wherein identifying step (b) is performed using flow cytometry.